Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00233623
Status:
WITHDRAWN
Last Update Posted:
2011-01-27
First Post:
2005-10-04
Brief Title:
Irinotecan 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Non-Comparative Multicentre Phase II Parallel-Group Trial Of ZD1839 Iressa In Combination With 5 Fluorouracil Leucovorin And Cpt-11 Irinotecan In Patients With Metastatic Colorectal Cancer
Status:
WITHDRAWN
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to determine if Iressa added to chemotherapy with Irinotecan 5Fluorouracil and Leucovorin can prolong the period of time without any disease worsening Time to Progression in patients with metastatic colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None